277 results on '"Kadiyala, Padma"'
Search Results
52. Zinc Finger MYND-Type Containing 8 (ZMYND8) is epigenetically regulated in mutant Isocitrate Dehydrogenase 1 (IDH1) glioma to promote radioresistance
53. Systemic Delivery of an Adjuvant CXCR4–CXCL12 Signaling Inhibitor Encapsulated in Synthetic Protein Nanoparticles for Glioma Immunotherapy
54. Using Single Cell Transcriptomics to Elucidate the Myeloid Compartment in Pancreatic Cancer
55. 121: INTERLEUKIN-8 IS A POTENTIAL MEDIATOR OF CHEMOTHERAPY RESPONSE IN PANCREATIC DUCTAL ADENOCARCINOMA
56. 24 TRACING PANCREATIC TUMOR EVOLUTION THROUGH SPACE AND TIME
57. 1056 ANALYSIS OF THE HEALTHY HUMAN PANCREAS REVEALS FREQUENT NEOPLASTIC LESIONS WITH A DISTINCT MICROENVIRONMENT
58. Abstract PO-098: Longitudinal profiling of pancreatic cancer patients identifies interleukin-8 as a mediator of myeloid-epithelial crosstalk
59. Impact of the Penny Stock Reform Act of 1990 on the Initial Public Offering Market *
60. S82 Longitudinal Immunoprofiling of Pancreatic Cancer Patients to Identify Mediators of Therapy Resistance
61. Systemic delivery of a CXCR4-CXCL12 signaling inhibitor encapsulated in synthetic protein nanoparticles for glioma immunotherapy
62. Genetic Alterations in Gliomas Remodel the Tumor Immune Microenvironment and Impact Immune-Mediated Therapies
63. The endoplasmic reticulum associated degradation adaptor Sel1L regulates T cell homeostasis and function
64. Endoplasmic reticulum associated degradation adaptor Sel1L regulates T cell survival and homeostasis
65. Mo1252 LEVERAGING ENDOSCOPIC FINE NEEDLE BIOPSIES TO PERFORM LONGITUDINAL PROFILING OF PANCREATIC TUMORS
66. Targeting gliomas with STAT3-silencing nanoparticles
67. A novel miR1983-TLR7-IFNβ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1
68. Asset allocation decisions of mutual fund investors
69. An Optimized Protocol for In Vivo Analysis of Tumor Cell Division in a Sleeping Beauty-Mediated Mouse Glioma Model
70. Abstract 1266: Mutant IDH1 alters epigenetic regulation to promote stemness in low grade glioma: Deciphering signaling pathways altered by mIDH1 inhibition
71. Abstract 3950: Spatiotemporal analysis of gliomas: Dynamics of mesenchymal multicellular structures as novel target for tumor treatment
72. Synthetic High-density Lipoprotein Nanodiscs for Personalized Immunotherapy Against Gliomas
73. Therapeutic Efficacy of Immune Stimulatory Thymidine Kinase and fms-like Tyrosine Kinase 3 Ligand (TK/Flt3L) Gene Therapy in a Mouse Model of High-Grade Brainstem Glioma
74. Immunotherapy for gliomas: shedding light on progress in preclinical and clinical development
75. Erratum: Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses
76. Inhibition of 2-Hydroxyglutrate Elicits Metabolic-reprograming and Mutant IDH1 Glioma Immunity
77. An optimized protocol for in vivo analysis of tumor cell division in a Sleeping Beauty-mediated mouse glioma model. v1
78. Isolation and Characterization of Immune Cells from the Tumor Microenvironment of Genetically Engineered Pediatric High Grade Glioma Models Using the Sleeping Beauty Transposon System v1
79. Laser Capture Microdissection of Glioma Subregions for Spatial and Molecular Characterization of Intratumoral Heterogeneity, Oncostreams, and Invasion
80. Prospects of biological and synthetic pharmacotherapies for glioblastoma
81. Fyn tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates antiglioma immune responses
82. Smart Money Flows Into ETFs and Investor Sentiment
83. Systemic Brain Tumor Delivery of Synthetic Protein Nanoparticles for Glioblastoma Therapy
84. Therapeutic efficacy of an immune stimulatory gene therapy strategy in a mouse model of high grade brainstem glioma
85. RDNA-03. AUTOPHAGY AS A NOVEL THERAPEUTIC TARGET IN MUTANT IDH1 GLIOMAS
86. TMIC-62. FYN, AN EFFECTOR OF ONCOGENIC RECEPTOR TYROSINE KINASES SIGNALING IN GLIOBLASTOMA, INHIBITS ANTI-GLIOMA IMMUNE RESPONSES: IMPLICATIONS FOR IMMUNOTHERAPY
87. GENE-32. SYNTHETIC LETHAL INTERACTIONS WITH IDH1R132H IN GLIOMA STEM-LIKE CELLS
88. PDTM-20. THE HISTONE MUTATION H3.3-G34R ENCOUNTERED IN PEDIATRIC HIGH GRADE GLIOMA MODIFIES THE TUMOR IMMUNE MICROENVIRONMENT RENDERING IT MORE PERMISSIVE FOR IMMUNE MEDIATED THERAPIES
89. TMIC-35. IDH1 MUTATION IN GLIOMA REPROGRAMS EARLY MYELOID DIFFERENTIATION IN THE BONE MARROW (BM) TO PRODUCE NON-IMUNESUPPRESSIVE NEUTROPHILS
90. TMIC-58. THE CELLULAR AND MOLECULAR BASIS FOR MESENCHYMAL TRANSFORMATION IN GLIOMAS
91. IMMU-03. SUPPRESSION OF ONCOMETABOLITE 2-HYDROXYGLUTRATE PRODUCED BY MUTANT IDH1 GLIOMA WITH AGI-5198 ENHANCES THE EFFICACY OF RADIOTHERAPY AND IMMUNE CHECKPOINT BLOCKADE ELICITING IMMUNOLOGICAL MEMORY
92. Ex ante estimation of a firm's distress risk parameters from bond transaction data
93. ADRs as leading indicators of exchange rates
94. Impact of the Penny Stock Reform Act of 1990 on the initial public offering market.
95. FYN tyrosine kinase, a downstream target of receptor tyrosine kinases, modulates anti-glioma immune responses
96. TMOD-08. ELUCIDATING EPIGENETIC MECHANISMS IN DIFFUSE INTRINSIC PONTINE GLIOMA HARBORING ACVR1 G328V AND H3.1 K27M
97. TMOD-02. CHARACTERIZATION OF THE TUMOR IMMUNE MICROENVIRONMENT IN A PEDIATRIC HIGH GRADE GLIOMA MOUSE MODEL HARBORING THE H3.3-G34R MUTATION
98. 3131 ONCOSTREAMS: NOVEL DYNAMICS PATHOLOGICAL MULTICELLULAR STRUCTURES INVOLVED IN GLIOBLATOMA GROWTH AND INVASION
99. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response
100. High-Density Lipoprotein-Mimicking Nanodiscs for Chemo-immunotherapy against Glioblastoma Multiforme
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.